Search for: "Pharmacia "
Results 41 - 60
of 173
Sort by Relevance
|
Sort by Date
18 Feb 2014, 3:18 pm
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Testosterone is a 19-carbon steroid hormone. [read post]
18 Feb 2014, 3:18 pm
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Testosterone is a 19-carbon steroid hormone. [read post]
18 Feb 2014, 3:18 pm
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Testosterone is a 19-carbon steroid hormone. [read post]
12 Feb 2014, 7:36 am
Abstract: The January 2012 decision of the Italian Competition Authority (“ICA”) to fine Pfizer and Pharmacia €10.6 million is an illustration of the more aggressive trend taken by competition authorities in the pharmaceutical sector. [read post]
19 Dec 2013, 4:56 pm
(Enlarged Board of Appeal in G2/98).Priority can be lost by:narrowing down the disclosure from the priority document in a manner which the invention could not be derived directly and unambiguously from it (Pharmacia Corp v Merck & Co Inc [2002] RPC 41); orwidening or generalizing from the priority disclosure (Beloit Technologies Inc and another v Valmet Paper Machinery Inc and another [1995] RPC 7005 and Unilin)The story continues in Part II. [read post]
9 Aug 2013, 1:55 pm
Pharmacia & Upjohn Co. v. [read post]
8 Jun 2013, 10:35 am
Sugen’s appeal against the revocation was fixed for hearing on May 14th 2013 subject to the undertaking given by the appellant (Sugen) that they will not use the revoked patent against the second respondent (Cipla) in other proceedings.According to the appellant (Sugen/Pharmacia) the opposition was not sustainable (second revocation decision) due to the following grounds, which are detailed below:Consideration of Section 25(2) (b):Sugen argued that Section 25(2) (b) should have not… [read post]
7 May 2013, 8:53 am
I do not detect anything in the decisions of the Court of Appeal in Pharmacia and Unilin Beheer which is inconsistent with this approach and in my judgment is one which this court should adopt. [read post]
15 Oct 2012, 1:24 am
As discussed here, shareholders first sued Pharmacia and certain of its directors and officers in 2003, alleging that the company had released only part of a long-term clinical study the company had commissioned on the side effects of the drug. [read post]
10 Oct 2012, 9:56 am
In the Appeals Court case Plaintiffs-Appellants Solutia, Inc. and Pharmacia Corporation (Solutia & Pharmacia) appealed the District Court's grant of summary judgment against their claims under § 107(a) of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). [read post]
6 Aug 2012, 8:08 am
VOL PHARMACIA LTDA. [read post]
20 Jul 2012, 9:10 am
Earlier CJEU rulings in Pharmacia, MIT, and Yissum had focused on the meaning of “product” within this provision. [read post]
29 Jun 2012, 12:06 pm
Pfizer and its partner, Pharmacia, were able to misrepresent Celebrex as a safer alternative because they only released the results of half of a yearlong study. [read post]
21 Jun 2012, 11:46 am
Pharmacia Corporation (f/k/a Monsanto Company)48. [read post]
17 Jun 2012, 3:52 pm
Research and Development communications and re-branding strategies for the company’s Warner-Lambert merger and Pharmacia acquisition. [read post]
30 May 2012, 1:37 pm
BIOGRAPHY AND CV CONTACT INFORMATION CLIENT LISTEXPERT WITNESS SERVICESMEDIACONGRESS LETTER ON BEHALF OF DR. [read post]
23 May 2012, 7:51 pm
Pharmacia Corp., 788 A.2d 544 (Del. [read post]
17 Apr 2012, 4:30 am
., Pharmacia Corp., and Pfizer, Inc., in the Circuit Court of St. [read post]
7 Mar 2012, 1:56 pm
Plaintiffs-Appellants Solutia, Inc. and Pharmacia Corporation (Solutia & Pharmacia) appeal the District Court's grant of summary judgment against their claims under § 107(a) of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). [read post]
15 Feb 2012, 7:42 am
BIOGRAPHY AND CV CONTACT INFORMATION CLIENT LISTEXPERT WITNESS SERVICESMEDIACONGRESS LETTER ON BEHALF OF DR. [read post]
